##semicolon##
щитовидная железа, жидкостная цитология, система Бетесда, мутация BRAF V600E, папиллярная карцинома.##submission.citations##
Haugen B.R., Alexander E.K., Bible K.C., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with a Thyroid Nodule and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. DOI: 10.1089/thy.2015.0020.
Ali S.Z., Baloch Z.W., Cochand-Priollet B., Schmitt F.C., Vielli P., Clark D.P. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023;33(9):1039-1044. DOI: 10.1089/thy.20 23.0141.
Xing M., Alzahrani A.S., Carson K.A., et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493-1501. DOI: 10.1001/ja-ma.2013.3190.
Patel K.N., Angell T.E., Babiarz J., et al. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019;5(2):204-212. DOI: 10.1001/jamaoncol.2018. 4616.
Rossi E.D., Pantanowitz L., Hornick J.L. A worldwide journey of thyroid cancer incidence centred on tumour histology. Lancet Diabetes Endocrinol. 2021;9(4):193-194. DOI: 10.1016/S2213-85 87(21)00049-8.
Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94(6):2092-2098. DOI: 10.1210/jc.2009-0247.